Pulse Biosciences (NASDAQ:PLSE) Downgraded to “Hold” at Maxim Group

Maxim Group lowered shares of Pulse Biosciences (NASDAQ:PLSEGet Rating) from a buy rating to a hold rating in a research report released on Wednesday morning, The Fly reports.

Separately, StockNews.com initiated coverage on shares of Pulse Biosciences in a research report on Saturday, September 17th. They issued a sell rating for the company.

Pulse Biosciences Stock Up 7.2 %

Shares of NASDAQ:PLSE opened at $1.49 on Wednesday. Pulse Biosciences has a fifty-two week low of $1.18 and a fifty-two week high of $24.58. The firm has a 50-day simple moving average of $1.58 and a 200 day simple moving average of $2.48. The company has a market cap of $55.32 million, a PE ratio of -0.74 and a beta of 1.97.

Pulse Biosciences (NASDAQ:PLSEGet Rating) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). Pulse Biosciences had a negative net margin of 2,866.34% and a negative return on equity of 186.19%. The business had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.55 million. During the same period in the prior year, the company earned ($0.57) EPS. As a group, research analysts forecast that Pulse Biosciences will post -1.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new position in shares of Pulse Biosciences in the fourth quarter valued at approximately $164,000. Advisor Group Holdings Inc. boosted its holdings in shares of Pulse Biosciences by 25.5% in the first quarter. Advisor Group Holdings Inc. now owns 25,878 shares of the company’s stock valued at $126,000 after acquiring an additional 5,265 shares in the last quarter. TIAA FSB bought a new position in shares of Pulse Biosciences in the second quarter valued at approximately $42,000. Occudo Quantitative Strategies LP boosted its holdings in shares of Pulse Biosciences by 217.3% in the second quarter. Occudo Quantitative Strategies LP now owns 58,383 shares of the company’s stock valued at $54,000 after acquiring an additional 39,981 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Pulse Biosciences in the first quarter valued at approximately $378,000. 8.34% of the stock is currently owned by institutional investors.

About Pulse Biosciences

(Get Rating)

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

Featured Articles

The Fly logo

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.